CJC-1295 DAC vs No DAC: Which Version Is Right for You?

DAC stands for Drug Affinity Complex. It is a maleimidopropionic acid group attached to the CJC-1295 peptide chain. After injection, this reactive group forms a covalent bond with serum albumin, the most abundant protein in your blood (Jetté et al., Bioconjug Chem, 2005).

Think of albumin as a freight train running a continuous loop through your bloodstream. CJC-1295 without DAC is a passenger standing on the platform: it arrives, delivers its signal to the pituitary in minutes, and disappears. CJC-1295 with DAC boards the train and rides it for days, delivering its GHRH signal to the pituitary over and over as albumin circulates.

The literal consequence: a single 2 mg injection of CJC-1295 with DAC elevated GH levels for 6 or more days in healthy adults. Mean GH levels increased 2 to 10-fold, and IGF-1 levels rose 1.5 to 3-fold above baseline, remaining elevated for 6-14 days (Teichman et al., J Clin Endocrinol Metab, 2006). Without DAC, the same base peptide clears in roughly 30 minutes, producing a single sharp GH pulse that returns to baseline within 2-3 hours.

The half-life gap between these two versions is not a minor difference. It is a 230-fold difference that dictates every aspect of the protocol.

A study in 21 healthy adults showed that weekly dosing of CJC-1295 with DAC at 30-60 mcg/kg produced dose-dependent IGF-1 increases of 1.5 to 3-fold that persisted for the full dosing interval (Teichman et al., J Clin Endocrinol Metab, 2006). The accumulation effect means that after 2-3 weeks of weekly injections, GH and IGF-1 levels remain continuously elevated rather than cycling up and down.

With the no-DAC version, you control the timing of each GH pulse. Inject before bed: you get a GH surge during deep sleep. Inject in the morning fasted: you get a lipolytic pulse while insulin is low. Miss a dose: your levels are back to baseline within hours. This granular control is why the no-DAC version remains the preferred choice in most research protocols. Track the half-life kinetics with the Peptide Half-Life Tracker.

Your pituitary naturally releases growth hormone in 6-12 discrete pulses per day, with the largest surge occurring during slow-wave sleep. Between pulses, GH drops to near-zero. This on-off pattern is not a flaw in human biology. It is the signal itself.

Pulsatile GH release activates lipolysis (fat breakdown) more effectively than continuous exposure. A study in GH-deficient adults found that pulsatile GH administration produced greater fat oxidation and protein synthesis than continuous infusion at the same total dose (Giustina & Veldhuis, Endocr Rev, 1998). The liver's GH receptors also appear to respond more robustly to pulse patterns, producing more IGF-1 per unit of GH when signaling arrives in bursts (Tannenbaum et al., Endocrinology, 2003).

CJC-1295 without DAC preserves this pulse architecture. Each injection creates a clean spike, and somatostatin resets the system between doses. Stack it with ipamorelin and you get a pulse 3-5x larger than either peptide alone, because ipamorelin works through the ghrelin receptor (GHSR) while Mod GRF 1-29 works through GHRH receptor. Two doors into the same room.

CJC-1295 with DAC overrides the pulse architecture. The pituitary receives continuous GHRH stimulation, which dampens somatostatin cycling and produces a "GH plateau" rather than spikes. Total GH output over 24 hours may be equal or higher, but the pattern is different. Some users prefer this for convenience. Others find that the sustained pattern produces more water retention and fewer of the discrete benefits associated with sharp pulses.

The right version depends on what you are trying to achieve. Here is how each version performs across the most common goals, based on GH physiology and user-reported outcomes.

The dosing protocols for these two versions look nothing alike. Confusing them is one of the most common mistakes in the GH peptide space.

No-DAC protocol (standard): Inject 100 mcg Mod GRF 1-29 combined with 200-300 mcg ipamorelin in the same syringe, 2-3 times daily. The pre-bed dose is the most important. Inject on an empty stomach: food (especially carbohydrates) raises insulin and blunts GH release. Wait 20-30 minutes after injection before eating.

DAC protocol (standard): Inject 2 mg subcutaneously once per week. Some users split to 1 mg twice weekly for slightly more even GH elevation. Timing relative to meals matters less because the albumin-bound peptide releases its signal continuously. However, some practitioners still recommend evening dosing.

For reconstitution volumes and syringe measurements, use the Peptide Reconstitution Calculator. For general injection technique, see the how to inject peptides guide.

The 20x difference in standard dosing between these versions creates real danger scenarios when users mix them up.

Both versions share common GH-related side effects because they act on the same receptor. The differences are in severity and pattern.

The DAC version's sustained GH elevation is responsible for its heavier side effect profile. Water retention is the most frequently cited complaint: users report 2-5 lbs of water weight gain in the first 2-3 weeks. This typically stabilizes but does not fully resolve while on protocol. The no-DAC version produces transient water retention that clears between doses.

The insulin sensitivity difference deserves attention. Sustained GH elevation opposes insulin action continuously. Pulsatile GH allows insulin sensitivity to recover between pulses. For anyone with prediabetes, metabolic syndrome, or a family history of type 2 diabetes, the no-DAC version carries lower metabolic risk. Monitor fasting glucose and HbA1c every 6-8 weeks regardless of which version you choose.

Both versions share the same contraindications: active cancer (GH and IGF-1 promote cell growth), pregnancy, pituitary disorders, and diabetic retinopathy. See the peptide safety guide for comprehensive contraindication information.

The CJC-1295 (no DAC) plus ipamorelin stack is the most widely used GH peptide combination in the research community. The pairing works because the two peptides activate different receptor pathways that converge on the same outcome.

Mod GRF 1-29 activates the GHRH receptor on pituitary somatotrophs, telling them to produce and release growth hormone. Ipamorelin activates the ghrelin receptor (GHS-R1a), which triggers the release of stored GH from a separate intracellular signaling cascade. Together, they produce GH pulses 3-5 times larger than either peptide alone (Bowers, J Clin Endocrinol Metab, 1998).

This synergy only works cleanly with the no-DAC version. Why? Because the sharp, time-limited GHRH signal from Mod GRF 1-29 synchronizes precisely with the sharp ghrelin signal from ipamorelin. Both peak at 15-30 minutes post-injection, creating a single coordinated burst. When the DAC version provides continuous GHRH stimulation, the ghrelin pulse from ipamorelin still occurs, but it lacks the coordinated amplification because the GHRH signal never "turns off" to reset.

Some users do stack DAC with ipamorelin, injecting ipamorelin 2-3x daily on top of a weekly DAC injection. This provides a sustained baseline plus acute pulses. The approach is valid but adds complexity and cost without clear evidence of superiority over the no-DAC plus ipamorelin standard.

Other stacking options:

• Mod GRF 1-29 + ipamorelin + BPC-157: For injury recovery with GH support. The elevated GH and IGF-1 accelerate collagen synthesis while BPC-157 drives localized tissue repair. See the peptide stacking guide for timing details.

• Mod GRF 1-29 + ipamorelin + MK-677: MK-677 provides oral, 24-hour ghrelin receptor activation while the injectable stack adds acute pulses. This is a high-GH protocol with more side effects (water retention, hunger from MK-677). See the MK-677 profile for dosing.

• CJC-1295 with DAC + hexarelin: Hexarelin is a more potent GHRP than ipamorelin but raises cortisol and prolactin. This stack is for advanced users only and requires monitoring. Hexarelin also desensitizes faster, limiting cycle length to 4-8 weeks.

For building your own stack, use the Peptide Stack Calculator and the Peptide Interaction Checker.

The total monthly cost depends on the version, dose, and whether you stack with a GHRP.

The DAC version uses less product per month in terms of injection count, but each injection requires a full 2 mg dose. A 2 mg vial is one dose. The no-DAC version uses smaller amounts per injection (100-150 mcg) but requires 60-90 injections per month when dosed three times daily.

Supply costs tip toward the DAC version: fewer syringes, fewer alcohol swabs, less bacteriostatic water. For a 12-week protocol, the DAC version saves roughly $30-50 on supplies alone. For help estimating your total peptide budget, use the Peptide Cost Calculator.

The hidden cost to consider: the no-DAC version is almost always used with ipamorelin, which adds $25-40 per month. The DAC version can be run standalone. When comparing total protocol cost including the GHRP, the two approaches end up within $20-30 per month of each other.

Your decision comes down to three factors: goals, lifestyle, and experience level.

Choose CJC-1295 without DAC (Mod GRF 1-29) if:

• You want to mimic natural, pulsatile GH release
• You plan to stack with ipamorelin (the gold-standard combo)
• Your primary goals are fat loss, sleep quality, or anti-aging
• You are comfortable with 2-3 daily subcutaneous injections
• You have metabolic concerns (prediabetes, insulin resistance)
• You want granular control over timing (fasted morning, pre-bed)

Choose CJC-1295 with DAC if:

• Injection convenience is your top priority
• You travel frequently and cannot maintain a 3x daily protocol
• Your primary goal is sustained IGF-1 elevation (confirmed by bloodwork)
• You prefer a simpler protocol with fewer daily decisions
• You do not plan to stack with a GHRP

Choose the hybrid approach if:

• You are experienced with peptides and want maximum benefit
• You want sustained baseline IGF-1 plus acute training-day pulses
• You are willing to manage a more complex protocol
• Your budget allows for both peptides plus ipamorelin

For beginners, the no-DAC version with ipamorelin is the standard starting point. It is more forgiving (short half-life means mistakes clear quickly), produces more physiological results, and pairs naturally with the most popular GHRP on the market. See getting started with peptides for a complete beginner framework.

1. Eating Before Injection (No-DAC)

Food raises insulin. Insulin suppresses GH release. Injecting Mod GRF 1-29 within 60 minutes of eating a meal (especially carbohydrates) can reduce the GH pulse by 50% or more. Always inject on an empty stomach: 1 hour after eating minimum, and wait 20-30 minutes after injection before your next meal.

2. Skipping the GHRP with No-DAC

Mod GRF 1-29 alone produces a moderate GH pulse. Paired with ipamorelin, the pulse is 3-5x larger. Running the no-DAC version without a GHRP is like driving in second gear: functional but leaving significant performance on the table.

3. Injecting DAC Too Frequently

Some users inject CJC-1295 with DAC every other day, treating it like the no-DAC version. With a 6-8 day half-life, this accumulates to supraphysiological levels. Water retention becomes severe, and insulin resistance risk climbs. Stick to once or twice weekly maximum.

4. Not Cycling

Both versions can desensitize pituitary GHRH receptors over time. Standard cycling is 8-16 weeks on, 4-6 weeks off. The DAC version may require longer off periods due to its sustained receptor stimulation. Monitor IGF-1 levels to guide your cycling decisions.

5. Storing Reconstituted Vials at Room Temperature

Both versions degrade faster outside the refrigerator. Reconstituted CJC-1295 lasts approximately 21-28 days at 2-8°C. At room temperature, potency drops measurably within 48 hours. See how long do reconstituted peptides last for complete shelf-life data.